GMA-161

N/A

Report date: 2022/07/01 11:36:13

Base Information

Drug NameGMA-161
Drug Alias NameAnti-CD16CD16 MabAnti-CD16 monoclonal antibody (Sanofi Genzyme/MacroGenics)GMA-161
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionLow affinity immunoglobulin gamma Fc region receptor III-A antagonists
TargetsLow affinity immunoglobulin gamma Fc region receptor III-A
Therapy Area/IndicationsPurpura, Thrombocytopenic, Idiopathic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSanofiMacrogenics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSanofi
Inactive CompaniesGenzyme Corp
Active IndicationsPurpura, Thrombocytopenic, Idiopathic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A